Teladoc Health, Inc. · NYSE:TDOC
Teladoc Health — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
20 slides from Teladoc Health's conference presentation, Jan 9, 2024
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January, 2024
Slide 2: Safe Harbor
Safe Harbor This presentation contains, and our officers may make, “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possib
Slide 3: Teladoc Health is the Global Leader in Virtual Healthcare
Teladoc Health is the Global Leader in Virtual Healthcare UNIQUE CAPABILITIES DELIVERED AT SCALE OUR MISSION Integrated Care Broad Product Empowering all Platform Portfolio people powered by data and spanning virtual & digital everywhere to advanced analytics at urgent, chronic, primary, scale menta
Slide 4: Operating in Two Segments
Operating in Two Segments INTEGRATED CARE BETTERHELP 56% +6.5% 44% +19% OF LTM1 REVENUE LTM1 REVENUE GROWTH OF LTM1 REVENUE LTM1 REVENUE GROWTH REVENUE Industry-leading integrated suite of telemedicine Industry-leading virtual mental health platform MIX & digital chronic care solutions 42% B2B go-to
Slide 5: Integrated Care Segment Strategy
Integrated Care Segment Strategy Chronic DRIVING OUTCOMES AT SCALE Condition I TE OF VIRTUAL & DIGIT Mental MARKET TAILWINDS Acute SU AL ED PR Health Care T OD RA OMPETITIVE AD UC • Buyer shift to Whole Person Care EG C T T A BLE VA N solutions IN S IN m e TA TA tco s at Ou s Sc ale G • Increased co
Slide 6: Integrated Care: Key Levers for Top Line Growth
Integrated Care: Key Levers for Top Line Growth DRIVE GREATER CLINICAL AND FINANCIAL VALUE FOR OUR CLIENTS NEW MEMBERS INCREASED REVENUE PER MEMBER Covered Life New Product Engagement TOTAL Penetration at Clients Penetration / Enrollment MARKET Clients Growth in client base to create new territory •
Slide 7: Long Runway for Increased Product Penetration
Long Runway for Increased Product Penetration % OF GENERAL MEDICAL POPULATIONS WITH ACCESS TO OTHER KEY TELADOC PRODUCTS (2021 VS 2023) Total General Medical Lives1 79% 2021 49% B2B Mental +800 of total growth in Health bps CCM enrollees is from increased penetration of the 2023 57% General Medical
Slide 8: Growing Chronic Care Enrollment
Growing Chronic Care Enrollment CCM CROSS-SALE & BUNDLING STRATEGY DRIVING INCREASED CLIENT PENETRATION AND REVENUE GROWTH CHRONIC CARE PROGRAM ENROLLMENT (000's) Multi-Product Chronic Care Bundling is Driving: ~30% 1,122 • Easier Contracting Path to Multi-Product Sales – ~80% of chronic care member
Slide 9: Chronic Care Land & Expand – Regional Health Plan Client Example
Chronic Care Land & Expand – Regional Health Plan Client Example DRIVING EXPANDED REVENUE BY CONVERTING STAND-ALONE DIABETES MANAGEMENT TO BROADER SUITE OF CCM AND TELEMED SERVICES TOTAL REVENUE Signed DM standalone in 2019 ASO and ACA. GM DM HTN $63m Signed MyStrength Digital. WM / DPP P360 myStren
Slide 10: General Medical Land & Expand – Mid-sized Employer Client Example
General Medical Land & Expand – Mid-sized Employer Client Example BUILDING ON GEN MED BASE WITH UPSELL OF P360 AND MENTAL HEALTH, AND ADDITION OF FULL SCOPE CCM OFFERING TOTAL REVENUE 2018 Signed GM. GM WM / DPP DM P360 HTN $600k 2022 $90k >6x Upsell to P360 (Capitated rate which includes Gen Med an
Slide 11: Using Data Science & AI to Drive Highly Personalized Recommendations at Scale
Using Data Science & AI to Drive Highly Personalized Recommendations at Scale MONTHLY ENROLLMENT RATES BY COHORT GEN AI PILOT Diabetes Management; OEP clients; Employer market 40% Member / 100+ Clinical Data versions 30% generated by AI Next Best Action Open AI Model 50%+ 20% lift in engagement Pers
Slide 12: Capitalizing on the Shift to Value Based Care
Capitalizing on the Shift to Value Based Care • 15% of CCM Bookings in 2023 with Fees At Risk for clinical measure impact Driving growth, • Sustained high clinical attainment based on performance competitive advantage, guarantees and value to clients • Supporting Health Plan clients with Gaps in Car
Slide 13: Market Leading DTC Mental Health Platform
Market Leading DTC Mental Health Platform BETTERHELP IS ADDRESSING STRUCTURAL ISSUES WITH A DIFFERENTIATED SOLUTION AT SCALE BETTERHELP Unmet Need Revenue [LHS] Nearly 1 in 3 Adults report symptoms of $1,200 Adjusted EBITDA [RHS] $160 REVENUE & anxiety and/or depression, yet less than half ADJ. EBIT
Slide 14: BetterHelp Competitive Advantages Driving Growth Into the Future
BetterHelp Competitive Advantages Driving Growth Into the Future 30K+ Efficient 1.5x KEY GROWTH DRIVERS Therapists Gross Profit to Ad Providing Spend Ratio3 Care2 Data driven Continued provider network expansion Marketing & Provider Pricing A&M spend optimization Scale Science Gross Margin improveme
Slide 15: Strong Track Record of Delivering Financial Results
Strong Track Record of Delivering Financial Results REVENUE ($M) AEBITDA ($M) FREE CASH FLOW ($M) MEMBERS (M) $130 300 90 $268 $100 $2,407 83 $247 78 250 73 $2,033 $214 $1,942 $1,769 56 200 $19 $17 $152 $5 150 $127 $1,094 100 $553 50 $32 $(80) 2019 2020 2021 2022 9-months 9-months 0 2019 2020 2021 2
Slide 16: Investment Highlights
Investment Highlights Virtual care industry leader Industry’s only comprehensive whole- person virtual care suite Market leading distribution across employer, health plan, and D2C channels Uniquely positioned to deliver data-driven integrated virtual care, creating better outcomes at lower cost Indu
Slide 17: Appendix
Teladoc. Appendix
Slide 18: Reconciliation of EBITDA and Adjusted EBITDA to Net Loss
Reconciliation of EBITDA and Adjusted EBITDA to Net Loss Nine Months Ended September 30, 2019 2020 2021 2022 2022 2023 Net loss (98,864) (485,136) (428,793) (13,659,531) (9,849,460) (191,478) Add: Goodwill impairment - - - 13,402,812 9,630,000 - Loss on extinguishment of debt - 9,077 43,748 - - - In
Slide 19: Reconciliation of Free Cash Flow
Reconciliation of Free Cash Flow Nine Months Ended September 30, 2019 2020 2021 2022 2022 2023 Net cash provided by (used in) $ 29,869 $ (53,511) $193,990 $ 189,292 $ 123,743 $ 219,939 operating activities Capital (3,510) (4,024) (8,534) (16,480) (10,285) (10,060) expenditures Capitalized (7,390) (2
Slide 20: Non-GAAP Financial Measures
Non-GAAP Financial Measures • EBITDA consists of net loss before interest income; interest expense; other expense (income), net, including foreign exchange gains or losses; provision for income taxes; depreciation and amortization; goodwill impairment; and loss on extinguishment of debt. Adjusted EB
Teladoc Health — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix